Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 1 mg, 5 mg, 10 mg) |
| Drug Class | Cortisol synthesis inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Summary
- Osilodrostat (Isturisa) is used for the treatment of adult patients with Cushing’s disease when pituitary surgery is not an option or has not been curative.
- A systematic review and meta-analysis, consisting of one document, was conducted to evaluate the effectiveness and safety of osilodrostat among other drugs in treating Cushing's disease.
- The study included 97 participants who were treated with osilodrostat; it showed a proportion of Cushing's Disease control at 66.4% (95% CI: 57.9, 74.3).
- This result indicates that osilodrostat had a higher rate of controlling the disease compared to cabergoline (35%), pasireotide (44%), ketoconazole (41%) but similar efficacy as metyrapone (66%).
- No superiority could be determined over another drug due to lack controlled studies comparing different treatments directly.
- The most common adverse events associated with each drug were not specified for osilodrostat in this analysis; however, hyperglycemia was noted for pasireotide users while dizziness and nausea were reported by those on cabergoline or metyrapone therapy, elevated transaminases occurred more frequently among ketoconazole-treated individuals.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Isturisa (osilodrostat) Prescribing Information. | 2020 | Recordati Rare Disease, Inc. Lebanon, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effectiveness of medical treatment of Cushing's disease: a systematic review and meta-analysis. | 2021 | Frontiers in Endocrinology |